Search research articles
Contact Us
Filters
Showing results (1-10 of 31) with videos related to
Page
of 4
Sort By:
Reproductive Biomedicine Online
|
March 14, 2009
Emergency contraception: how does it work?
David T Baird
Best Practice & Research. Clinical Obstetrics & Gynaecology
|
June 4, 2002
Medical abortion in the first trimester
David T Baird
BJOG : an International Journal of Obstetrics and Gynaecology
|
November 28, 2002
A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy
Julia Bartley, David T Baird
Acta Obstetricia Et Gynecologica Scandinavica
|
February 7, 2019
The development of ovarian tissue cryopreservation in Edinburgh: Translation from a rodent model through validation in a large mammal and then into clinical practice
Richard A Anderson, David T Baird
The Journal of Clinical Endocrinology and Metabolism
|
January 15, 2002
Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days
Audrey Brown, Linan Cheng, Suiqing Lin, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
March 26, 2004
Long-term ovarian function in sheep after ovariectomy and autotransplantation of cryopreserved cortical strips
David T Baird, Bruce Campbell, Carlos de Souza, et al.
Endocrinology
|
December 20, 2003
Evidence of a role for follicle-stimulating hormone in controlling the rate of preantral follicle development in sheep
Bruce K Campbell, Evelyn E Telfer, Robert Webb, et al.
Human Reproduction (Oxford, England)
|
June 30, 2006
Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor
Nitish Narvekar, Hilary O D Critchley, Linan Cheng, et al.
Contraception
|
October 17, 2003
A single dose of mifepristone (200 mg) in the immediate preovulatory phase offers contraceptive potential without cycle disruption
Audrey Brown, Alistair Williams, Sharon Cameron, et al.
Fertility and Sterility
|
February 6, 2003
A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment
Peter Y K Yong, Sandra Brett, David T Baird, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 31) with videos related to
Sort By:
Page
of 4
Reproductive Biomedicine Online
|
March 14, 2009
Emergency contraception: how does it work?
David T Baird
Best Practice & Research. Clinical Obstetrics & Gynaecology
|
June 4, 2002
Medical abortion in the first trimester
David T Baird
BJOG : an International Journal of Obstetrics and Gynaecology
|
November 28, 2002
A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy
Julia Bartley, David T Baird
Acta Obstetricia Et Gynecologica Scandinavica
|
February 7, 2019
The development of ovarian tissue cryopreservation in Edinburgh: Translation from a rodent model through validation in a large mammal and then into clinical practice
Richard A Anderson, David T Baird
The Journal of Clinical Endocrinology and Metabolism
|
January 15, 2002
Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days
Audrey Brown, Linan Cheng, Suiqing Lin, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
March 26, 2004
Long-term ovarian function in sheep after ovariectomy and autotransplantation of cryopreserved cortical strips
David T Baird, Bruce Campbell, Carlos de Souza, et al.
Endocrinology
|
December 20, 2003
Evidence of a role for follicle-stimulating hormone in controlling the rate of preantral follicle development in sheep
Bruce K Campbell, Evelyn E Telfer, Robert Webb, et al.
Human Reproduction (Oxford, England)
|
June 30, 2006
Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor
Nitish Narvekar, Hilary O D Critchley, Linan Cheng, et al.
Contraception
|
October 17, 2003
A single dose of mifepristone (200 mg) in the immediate preovulatory phase offers contraceptive potential without cycle disruption
Audrey Brown, Alistair Williams, Sharon Cameron, et al.
Fertility and Sterility
|
February 6, 2003
A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment
Peter Y K Yong, Sandra Brett, David T Baird, et al.
Page
of 4